Phase 3 RCT in 141 adolescents with heterozygous familial hypercholesterolaemia on statins: inclisiran lowered LDL cholesterol by 27.1% vs a 1.4% rise with placebo at day 330 (difference −28.5%); injection site reactions 16% vs 6%, all mild.
RCTn = 141
Wiegman et al. Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial